Trial Profile
A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Panobinostat (Primary)
- Indications Gastrointestinal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- 12 Sep 2011 Planned End Date changed from 1 Jun 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jul 2010 New trial record